Authors
Latest:
Utility of the 21-Gene Recurrence Score in Node-Positive Breast CancerABSTRACT The 21-gene Recurrence Score (RS) assay has been validated as both a prognostic and predictive tool in node-negative (pN0), estrogen receptor–positive (ER+), HER2-negative (HER2–) breast cancer. A large body of evidence supports the clinical utility of the RS in the node positive (pN+) population as well. Retrospective analyses of archived tissue from multiple clinical trials have found the RS to be prognostic in both endocrine therapy (ET)-treated and chemotherapy-treated patients with pN+ disease. Distribution of RS results in pN+ patients have also been consistent with those of pN0 populations. Data from the SWOG 8814 trial and large population-based registries further support the prognostic and potential predictive value of the RS. Specifically, patients with 1 to 3 positive nodes and RS less than 18 derived negligible benefit from adjuvant chemotherapy in these studies. In the prospective West German Study Group PlanB and ADAPT trials, pN+ patients with RS less than 11 and RS ≤25, respectively, who were treated with ET alone experienced excellent outcomes. Finally, 5-year results of the RxPONDER clinical trial randomizing patients with 1 to 3 positive nodes and RS ≤25 to ET alone vs ET plus chemotherapy confirmed an absence of chemotherapy benefit in postmenopausal patients. Clinical practice guidelines support use of the RS in the pN+, ER+/HER2– population, and many institutions have adopted the RS to guide clinical decision-making, resulting in a net reduction of adjuvant chemotherapy use. This review highlights the existing data supporting the prognostic and predictive ability of the RS in pN+ disease, current practice patterns related to RS use in this population, and emerging applications.
Latest:
Shorter Time to Treatment Is Associated With Improved Survival in Rural Patients With Breast Cancer Despite Other Adverse Socioeconomic FactorsMinh-Tri Nguyen, MD, and colleagues investigate the association between time to treatment, socioeconomic status, and clinical outcomes among rural and urban patients with breast cancer.
Latest:
Expert Perspectives on 2024 ASCO GI Cancers Symposium Trial UpdatesJun Gong, MD, and Daneng Li, MD, spoke about trials they feel can impact the gastrointestinal space during a CancerNetwork® X Space.
Latest:
Profilin 1 Protein and Its Implications for CancersProfilin 1, or PFN1, is a key actin-binding protein that is involved in various cellular activities, such as cell motility, survival, and membrane trafficking. By summarizing the functions of PFN1 in cancer, investigators hope to better understand the mechanisms of PFN1 in cancer progression.
Latest:
Trevor M. Feinstein, MD, Reviews QOL Analysis of DUBLIN-3 Trial Comparing Docetaxel With or Without Plinabulin in NSCLCTrevor M. Feinstein, MD, spoke about how quality of life was improved for patients with EGFR wild-type stage IIIB/IV non–small cell lung cancer receiving plinabulin in addition to docetaxel the phase 3 DUBLIN-3 trial.
Latest:
Unmet Needs and Future Perspectives in Newly-Diagnosed and Relapsed Multiple MyelomaClosing out their discussion, the panel shares remaining unmet needs in the treatment of newly-diagnosed and relapsed multiple myeloma.
Latest:
Use of Neoadjuvant Chemotherapy in Elderly Patients With Muscle-Invasive Bladder Cancer: A Population-Based Study, 2006-2017Patients 70 years or older that received neoadjuvant chemotherapy and radical cystectomy had better overall survival than those undergoing radical cystectomy alone.
Latest:
Oncology Peer Review On-The-Go: Germline Testing in Prostate Cancer: When and Who to TestThe recent episode of the "Oncology Peer Review On-The-Go" podcast features Alexandra Sokolova, MD, discussing her article on germline testing and NCCN guidelines for patients with prostate cancer.
Latest:
John N. Allan, MD, on the Impact of First-Line Ibrutinib in Patients with CLL, TP53 AberrationsThis pooled analysis from 4 clinical trials suggested that though patients with TP53 aberrations remain at risk for progression, first-line treatment with ibrutinib has meaningfully improved the poor prognosis in this high-risk population.
Latest:
Shubham Pant, MD, Highlights the Potential of ELI-002 2P to Treat MRD in KRAS-Mutant Solid MalignanciesShubham Pant, MD, spoke to the potential of ELI-002 2P as a treatment for minimal residual disease positivity in patients with KRAS-mutant solid tumors.
Latest:
Unmet Needs and the Future of Kidney CancerDrs Tom Powles and Brian Shimkus muse on the unmet needs of kidney cancers and treatments on the horizon to look forward to.
Latest:
Relacorilant May Be ‘Synergistic’ With Nab-Paclitaxel in Ovarian CancerInvestigators of a phase 2 study suggest that relacorilant may add to a ‘sparse’ field of effective treatment options for patients with platinum-resistant or refractory ovarian cancer.
Latest:
Future Perspectives in HER2+ mBCThe panel closes their discussion by musing on the future of HER2 mBC treatments.
Latest:
The Effect of Prior Cancer on Survival of Patients With ThymomaShilong Wu, MD, and co-authors discuss how patients with thymoma are affected by prior cancer history.
Latest:
Unmet Needs and Future Directions in the Management of Multiple MyelomaExperts from Ochsner Health close out their panel on multiple myeloma management by identifying unmet needs and sharing excitement for future evolution in the treatment landscape.
Latest:
Utility of the 21-Gene Recurrence Score in Node-Positive Breast CancerABSTRACT The 21-gene Recurrence Score (RS) assay has been validated as both a prognostic and predictive tool in node-negative (pN0), estrogen receptor–positive (ER+), HER2-negative (HER2–) breast cancer. A large body of evidence supports the clinical utility of the RS in the node positive (pN+) population as well. Retrospective analyses of archived tissue from multiple clinical trials have found the RS to be prognostic in both endocrine therapy (ET)-treated and chemotherapy-treated patients with pN+ disease. Distribution of RS results in pN+ patients have also been consistent with those of pN0 populations. Data from the SWOG 8814 trial and large population-based registries further support the prognostic and potential predictive value of the RS. Specifically, patients with 1 to 3 positive nodes and RS less than 18 derived negligible benefit from adjuvant chemotherapy in these studies. In the prospective West German Study Group PlanB and ADAPT trials, pN+ patients with RS less than 11 and RS ≤25, respectively, who were treated with ET alone experienced excellent outcomes. Finally, 5-year results of the RxPONDER clinical trial randomizing patients with 1 to 3 positive nodes and RS ≤25 to ET alone vs ET plus chemotherapy confirmed an absence of chemotherapy benefit in postmenopausal patients. Clinical practice guidelines support use of the RS in the pN+, ER+/HER2– population, and many institutions have adopted the RS to guide clinical decision-making, resulting in a net reduction of adjuvant chemotherapy use. This review highlights the existing data supporting the prognostic and predictive ability of the RS in pN+ disease, current practice patterns related to RS use in this population, and emerging applications.
Latest:
Oncology Peer Review On-The-Go: Minimal Residual Disease–Directed Adjuvant Therapy for Patients With Early-Stage Colon CancerLead author Ibrahim Halil Sahin, MD, spoke with CancerNetwork® about his work investigating postoperative circulating tumor DNA dynamics in early-stage colon cancer as part of the CIRCULATE-US trial published in the journal ONCOLOGY®.
Latest:
Adam J. Gadzinski, MD, MS, on Up-and-Coming Research for Urologic OncologyThe expert in urologic oncology spoke about new innovations that he believes will aid in treating patients with urologic cancers.
Latest:
Managing Hematological Toxicities Associated with Bispecifics in MMExperts on multiple myeloma provide insights on the management of hematological toxicities associated with bispecific antibodies.
Latest:
Investigating the Use of Circulating Tumor DNA in Early-Stage Colon CancerArdaman Shergill, MD, and Aparna Raj Parikh, MD, explore ongoing clinical investigations evaluating the use of circulating tumor DNA in the treatment of early-stage colon cancer.
Latest:
The Effect of Prior Cancer on Survival of Patients With ThymomaShilong Wu, MD, and co-authors discuss how patients with thymoma are affected by prior cancer history.
Latest:
Thierry Facon, MD, Looks to the Future of Therapy for Multiple Myeloma at 2022 ASCOThierry Facon, MD, spoke about treatment combinations that have seen success in patients with multiple myeloma, as well as where future research should be focused.
Latest:
Pediatric Locally Advanced Synovial Sarcoma: What Would Be the Best Treatment Option?KEY POINTS • Synovial sarcomas are often mistreated with unplanned tumor resection. • Attention from specialists early in the course of SS can minimize the risk of recurrence, metastases, and the necessity for resurgery, all of which are increased with unplanned tumor resection. • Chemotherapy alone does not provide sufficient local control of the tumor. • Resurgery, in conjunction with radiotherapy and chemotherapy, is the best choice of management for this patient.
